WHIM PDX Models
Inotiv offers the highly regarded and well characterized Washington University Human in Mouse (WHIM) PDX models. This broad collection of breast cancer PDX cells encompass all of the major molecular subtypes and other notable attributes such as treatment resistance and sensitivity. Search by these criteria below.
Subject to availability
Order today
Washington University Human in Mouse (WHIM) PDX models
| WHIM | Tumor Site | Status ER / PR / HER2 |
Details |
|---|---|---|---|
| WHIM2 | Primary: Breast | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: WT PIK3CA genotype2: WT p53 genotype: S166S insertion Whole genome sequenced: No Exome sequenced: Unknown RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: p90RSK_pT359 PAM50 subtype originating tumor: Basal PAM50 subtype early passage PDX: Basal PAM50 subtype late passage PDX: Basal Treatment prior to sample grafting: N/A Treatment post sample grafting: Neoadj. DD doxorubicin, Cyclophosphomide, followed by Paclitaxel; Adj. chest wall radiation, Tamoxifen; Brain met; Pathology specimen type: Surgery core primary Pathology stage: 3A Stage at sample grafting: 4 Pathology: Ductal, Lobular Patient tumor grade: 3 Age at diagnosis: 44 Family history: None Overall survival (months): 11 Patient race: African American Propagated in NSG @ Inotiv: x Completed efficacy study: No Estradiol response: Unknown WHIM number: 2 Notes: Same patient as WHIM 5 |
| WHIM3 | Primary: Breast | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: WT PIK3CA genotype2: WT p53 genotype: WT Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Src_pY527 PAM50 subtype originating tumor: HER2-E PAM50 subtype early passage PDX: PAM50 subtype late passage PDX: Treatment prior to sample grafting: N/A Treatment post sample grafting: Gemcitabine x1 Pathology specimen type: Unknown Pathology stage: Unknown Stage at sample grafting: Unknown Pathology: Unknown Patient tumor grade: Unknown Age at diagnosis: Unknown Family history: Unknown Overall survival (months): Unknown Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 3 Notes: |
| WHIM4 | Metastasis: Skin | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: WT PIK3CA genotype2: WT p53 genotype: R175H Whole genome sequenced: Yes Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: p27_pT198 PAM50 subtype originating tumor: Basal PAM50 subtype early passage PDX: Basal PAM50 subtype late passage PDX: Basal Treatment prior to sample grafting: Adj. Herceptin; Gem, Paclitaxel, Herceptin; Capecitabine Treatment post sample grafting: Bevacizumab, Docetaxel chest wall radiation, Tamoxifen; Brain met; Pathology specimen type: Core abdominal wall recurrence Pathology stage: PathCR Stage at sample grafting: 4 Pathology: Ductal Patient tumor grade: 3 Age at diagnosis: 49 Family history: None Overall survival (months): 37 Patient race: African American Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 4 Notes: |
| WHIM5 in stock |
Metastasis: Brain | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: WT PIK3CA genotype2: WT p53 genotype: S166S insertion Whole genome sequenced: Yes Exome sequenced: No RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: p90RSK_pT359 PAM50 subtype originating tumor: Basal PAM50 subtype early passage PDX: Basal PAM50 subtype late passage PDX: Basal Treatment prior to sample grafting: Neoadj. DD doxorubicin, Cyclophosphomide, followed by Paclitaxel; Adj. chest wall radiation, Tamoxifen; Brain met Treatment post sample grafting: N/A Pathology specimen type: Surgical specimen, brain – posterior fossa; surgery core primary Pathology stage: 3A Stage at sample grafting: 4 Pathology: Ductal, Lobular Patient tumor grade: 3 Age at diagnosis: 44 Family history: Unknown Overall survival (months): 11 Patient race: African American Propagated in NSG @ Inotiv: x Completed efficacy study: x Estradiol response: Unknown WHIM number: 5 Notes: Same patient as WHIM 2 |
| WHIM6 | Primary: Breast | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: WT PIK3CA genotype2: WT p53 genotype: WT Whole genome sequenced: Yes Exome sequenced: No RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: PRAS40_pT246 PAM50 subtype originating tumor: Basal PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: N/A Treatment post sample grafting: neo 5FU, epirubicin, cyclophosphamide; Left Breast Excision; chest wall radiation; Nab-Paclitaxel; Capecitabine; 5FU, Epirubicin, Cyclophosphamide; Doxorubicin; Gemcitabine; Navelbine Pathology specimen type: Unknown Pathology stage: Unknown Stage at sample grafting: Unknown Pathology: Unknown Patient tumor grade: Unknown Age at diagnosis: Unknown Family history: Unknown Overall survival (months): Unknown Patient race: African American Propagated in NSG @ Inotiv: x Completed efficacy study: x Estradiol response: Unknown WHIM number: 6 Notes: |
| WHIM8 in stock |
Metastasis: Skin | ER- / PR- / HER2+ | ESR1 genotype: WT PIK3CA genotype2: WT p53 genotype: Y234H Whole genome sequenced: Yes Exome sequenced: No RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Shc_pY317 PAM50 subtype originating tumor: Basal PAM50 subtype early passage PDX: HER2-E PAM50 subtype late passage PDX: HER2-E Treatment prior to sample grafting: Adj. Docetaxol, Doxorubicin, Cylcophosphamide; Tamoxifen; Local recurrence Chest Wall; Anastrozole; Liver met; Carboplatin, Paclitaxel, and Herceptin; Navelbine and Herceptin; Gemcitabine and Herceptin; Herceptin and Capecitabine; 5FU, Epirubicin, Cyclophosphomide; radiation; Nab-Paclitaxel and Herceptin; Capecitabine and Lapatinib Treatment post sample grafting: CCI-779; Docetaxol and Bevacizumab Pathology specimen type: Punch Chestwall Pathology stage: 2B Stage at sample grafting: 4 Pathology: Ductal Patient tumor grade: 3 Age at diagnosis: 37 Family history: Maternal Aunt Overall survival (months): 113 Patient race: Caucasian Propagated in NSG @ Inotiv: x Completed efficacy study: No Estradiol response: Unknown WHIM number: 8 Notes: |
| WHIM9 | Metastasis: Skin | ER+ / PR+ / HER2- | ESR1 genotype: WT PIK3CA genotype2: H1047R p53 genotype: WT Whole genome sequenced: Yes Exome sequenced: No RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Akt_pS474 PAM50 subtype originating tumor: Luminal A PAM50 subtype early passage PDX: Luminal B PAM50 subtype late passage PDX: Luminal B Treatment prior to sample grafting: Adj. radiation; Letrozole and Zoladex; Letrozole Treatment post sample grafting: Fulvestrant +/- Lapatinib on protocol; Aromasin; Capecitabine; Tamoxifen; Estradiol; Doxorubicin, Doxorubicin + CCI-779; Megace; Nab-Paclitaxel Pathology specimen type: Punch Chestwall Pathology stage: N/A Stage at sample grafting: 4 Pathology: Ductal Patient tumor grade: 3 Age at diagnosis: 47 Family history: Unknown Overall survival (months): 129 Patient race: African American Propagated in NSG @ Inotiv: x Completed efficacy study: No Estradiol response: Independent WHIM number: 9 Notes: |
| WHIM10 | Primary: Breast | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: WT PIK3CA genotype2: WT p53 genotype: Y220C Whole genome sequenced: No Exome sequenced: Unknown RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: N/A PAM50 subtype originating tumor: Basal PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Unknown Treatment post sample grafting: Unkown Pathology specimen type: Unknown Pathology stage: Unknown Stage at sample grafting: Unknown Pathology: Unknown Patient tumor grade: Unknown Age at diagnosis: Unknown Family history: Unknown Overall survival (months): Unknown Patient race: Unknown Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 10 Notes: |
| WHIM11 in stock |
Primary: Breast | ER+ / PR- / HER2- | ESR1 genotype: WT PIK3CA genotype2: WT p53 genotype: D148X insertion Whole genome sequenced: Yes Exome sequenced: No RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: p70S6K_pT389 PAM50 subtype originating tumor: HER2-E PAM50 subtype early passage PDX: Luminal B PAM50 subtype late passage PDX: Her2-E Treatment prior to sample grafting: Letrozole, radiation Treatment post sample grafting: Fulvestrant +/- Lapatinib on study; Exemestane; mastectomy with LN dissection, chest wall radiation; radiation to spine; brain met; whole brain radiation; Paclitaxel, Bevacizumab; Capecitabine; Quadramet given for pain; Anastrozole Pathology specimen type: Surgery core primary Pathology stage: 4 Stage at sample grafting: 4 Pathology: Ductal Patient tumor grade: 3 Age at diagnosis: 40 Family history: Paternal Grandmother Overall survival (months): 37 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Independent WHIM number: 11 Notes: |
| WHIM12 | Primary: Breast | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: WT PIK3CA genotype2: WT p53 genotype: R248Q Whole genome sequenced: Yes Exome sequenced: No RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: AKT_pT308 PAM50 subtype originating tumor: Claudin Low PAM50 subtype early passage PDX: Claudin Low PAM50 subtype late passage PDX: Claudin Low Treatment prior to sample grafting: N/A Treatment post sample grafting: Adj. 5FU, Epirubicin, Cyclophosphamide, followed by Docetaxel; chest wall radiation; relapse; Paclitaxel, Bevacizumab; Bevacizumab held sec to low EF; Paclitaxel, Carboplatin Pathology specimen type: Surgery - Primary Pathology stage: 2B Stage at sample grafting: 2B Pathology: Metaplastic Patient tumor grade: 3 Age at diagnosis: Unknown Family history: Unknown Overall survival (months): 12 Patient race: Caucasian Propagated in NSG @ Inotiv: x Completed efficacy study: No Estradiol response: Unknown WHIM number: 12 Notes: |
| WHIM13 | Metastasis: Skin | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: WT PIK3CA genotype2: WT p53 genotype: C238Y Whole genome sequenced: Yes Exome sequenced: No RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Src_pY527 PAM50 subtype originating tumor: Basal PAM50 subtype early passage PDX: Basal PAM50 subtype late passage PDX: Basal Treatment prior to sample grafting: Neoadj. Doxorubicin, Cyclophosphamide + Docetaxol; adjuvant radiation- whole breast andregional node; ipsilateral breast recurrence; bilateral mastectomies; no treatment; chest wall recurrence; chest wall radiation; Nab-Paclitaxel, Bevacizumab x4 cycles; chemo break Treatment post sample grafting: Radiation to chest wall and regional nodes; liver and lung met; Capecitabine; Doxorubicin; Nab-Paclitaxel, Bevacizumab, Carboplatin, Gemcitabine Pathology specimen type: Punch -skin recurrence, surgery – chest wall skin recurrence Pathology stage: 2A Stage at sample grafting: 4 Pathology: Ductal, Lobular Patient tumor grade: 2 Age at diagnosis: 42 Family history: Maternal Aunt Overall survival (months): 44 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 13 Notes: |
| WHIM14 in stock |
Metastasis: Skin | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: WT PIK3CA genotype2: WT p53 genotype: I195T Whole genome sequenced: Yes Exome sequenced: RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: N/A PAM50 subtype originating tumor: Basal PAM50 subtype early passage PDX: PAM50 subtype late passage PDX: Treatment prior to sample grafting: Treatment post sample grafting: Pathology specimen type: Pathology stage: Stage at sample grafting: Pathology: Patient tumor grade: Age at diagnosis: Family history: Overall survival (months): Patient race: Caucasian Propagated in NSG @ Inotiv: x Completed efficacy study: Estradiol response: WHIM number: 14 Notes: |
| WHIM16 in stock |
Metastasis: Skin | ER+ / PR+ / HER2- | ESR1 genotype: AMP PIK3CA genotype2: H1047R p53 genotype: R248W Whole genome sequenced: Yes Exome sequenced: No RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: 4E-BP1_pT37 PAM50 subtype originating tumor: Luminal B PAM50 subtype early passage PDX: Luminal A PAM50 subtype late passage PDX: Luminal B Treatment prior to sample grafting: 8 cycles of adj. DD doxorubicin, Cylcophosphomide followed by Gemcitabine; radiation to right breast and axilla; Exemestane; recurrence to bone; Fulvestrant; palliative radiation to thoracic spine; Capecitabine; Estradiol Treatment post sample grafting: Paclitaxel, Bevacizumab Pathology specimen type: Punch -Skin recurrence Pathology stage: 3A Stage at sample grafting: 4 Pathology: Ductal Patient tumor grade: 3 Age at diagnosis: 64 Family history: Mother Maternal Aunt (x2) Overall survival (months): 56 Patient race: Caucasian Propagated in NSG @ Inotiv: x Completed efficacy study: x Estradiol response: Responsive WHIM number: 16 Notes: |
| WHIM18 in stock |
Metastasis: Skin | ER+ / PR+ / HER2- | ESR1 genotype: ESR1 YAP1 PIK3CA genotype2: E545K p53 genotype: WT Whole genome sequenced: Yes Exome sequenced: Unknown RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: ER-alpha_pS118 PAM50 subtype originating tumor: Luminal A PAM50 subtype early passage PDX: Luminal B PAM50 subtype late passage PDX: Luminal B Treatment prior to sample grafting: Letrozole; Exemestane; Fulvestrant Treatment post sample grafting: Capecitabine; Paclitaxel, Bevacizumab; Tamoxifen; Radiation to the calvarium completed; Doxil Pathology specimen type: Punch - Primary Pathology stage: 4 Stage at sample grafting: 4 Pathology: Ductal Patient tumor grade: 2 Age at diagnosis: 57 Family history: None Overall survival (months): 31 Patient race: African American Propagated in NSG @ Inotiv: x Completed efficacy study: x Estradiol response: Independent WHIM number: 18 Notes: |
| WHIM20 in stock |
Metastasis: Skin | ER+ / PR+ / HER2- | ESR1 genotype: Y537S PIK3CA genotype2: E542K p53 genotype: C182X Whole genome sequenced: Yes Exome sequenced: No RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: PDK1_pS241 PAM50 subtype originating tumor: Luminal B PAM50 subtype early passage PDX: Luminal A PAM50 subtype late passage PDX: Luminal B Treatment prior to sample grafting: Adj. Docetaxol, Carboplatin Alternating with Epirubicin, Cyclophosphomide x4 cycles; radiation; Tamoxifen; first recurrence; Docetaxol, Carboplatin; Letrozole; Fulvestrant; Vinorelbine, Capecitabine; Capecitabine, Fulvestrant; Capecitabine; Paclitaxel, Bevacizumab, bev held multiple times; Paclitaxel Treatment post sample grafting: IMC-A12, Temsirolimus on study; Exemestane; Estradiol; doxorubicin liposomal; methotrexate, cyclophosphomide; radiation to right face and neck; Eribulin Pathology specimen type: Punch - Skin right clavicle Pathology stage: 3A Stage at sample grafting: 4 Pathology: Ductal, Lobular Patient tumor grade: 1 Age at diagnosis: 36 Family history: Mother Overall survival (months): 37 Patient race: Caucasian Propagated in NSG @ Inotiv: x Completed efficacy study: x Estradiol response: Independent WHIM number: 20 Notes: Same Patient as WHIM23 |
| WHIM21 | Primary: Breast | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: WT PIK3CA genotype2: WT p53 genotype: P151H Whole genome sequenced: Yes Exome sequenced: RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Chk1_pS345 PAM50 subtype originating tumor: Basal PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Neoadj. Doxorubicin, Cyclophosphamide followed by Paclitaxel Treatment post sample grafting: Recurrence; radiation to chest wall and whole brain; Capecitabine, Ixabepilone Pathology specimen type: Unknown Pathology stage: Unknown Stage at sample grafting: Unknown Pathology: Unknown Patient tumor grade: Unknown Age at diagnosis: Unknown Family history: Unknown Overall survival (months): Unknown Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 21 Notes: |
| WHIM22 | Metastasis: Skin | ER- / PR- / HER2+ | ESR1 genotype: WT PIK3CA genotype2: WT p53 genotype: C275F Whole genome sequenced: No Exome sequenced: Unknown RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: EGFR_pY1068 PAM50 subtype originating tumor: Basal PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Adj. Doxorubicin, Cyclophosphamide, breast radiation, Paclitaxel, Herceptin, Herceptin 6/11/2007, Tamoxifen, local recurrance; Paclitaxel, Carboplatin, Herceptin; mastectomy; chest wall recurrence; Anastrozole Treatment post sample grafting: Abraxane, Bevacizumab, Anastrozole Pathology specimen type: Unknown Pathology stage: Unknown Stage at sample grafting: Unknown Pathology: Unknown Patient tumor grade: Unknown Age at diagnosis: Unknown Family history: Unknown Overall survival (months): Unknown Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 22 Notes: |
| WHIM23 | Metastasis: Node | ER+ / PR+ / HER2- | ESR1 genotype: Y537S PIK3CA genotype2: E542K p53 genotype: C182X Whole genome sequenced: No Exome sequenced: Unknown RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Rb_pS807_S811 PAM50 subtype originating tumor: Luminal B PAM50 subtype early passage PDX: Luminal A PAM50 subtype late passage PDX: Luminal B Treatment prior to sample grafting: Adj. Docetaxol, Carboplatin Alternating with Epirubicin, Cyclophosphomide x4 cycles; radiation; Tamoxifen; first recurrence; Docetaxol, Carboplatin; Letrozole; Fulvestrant; Vinorelbine, Capecitabine; Capecitabine, Fulvestrant; Capecitabine; Paclitaxel, Bevacizumab, bev held multiple times; Paclitaxel; IMC-A12, Temsirolimus on study; Exemestane Treatment post sample grafting: Estradiol; doxorubicin liposomal; methotrexate, cyclophosphomide; radiation to right face and neck; Eribulin Pathology specimen type: Punch - Skin right clavicle Pathology stage: 3A Stage at sample grafting: 4 Pathology: Ductal, Lobular Patient tumor grade: 1 Age at diagnosis: 36 Family history: Mother Overall survival (months): 97 Patient race: Caucasian Propagated in NSG @ Inotiv: x Completed efficacy study: No Estradiol response: Independent WHIM number: 23 Notes: Same Patient as WHIM20 |
| WHIM24 | Primary: Breast | ER+ / PR+ / HER2- | ESR1 genotype: E380Q PIK3CA genotype2: H1047K p53 genotype: WT Whole genome sequenced: Yes Exome sequenced: Unknown RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: ER-alpha_pS118 PAM50 subtype originating tumor: Luminal B PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Adj. Adriamycin, Cyclophosphomide bilateral breast radiation; Tamoxifen; recurrence, Docetaxol, Exemestane, Capecitabine, Doxorubicin liposomal x1 dose d/c due to high blood sugars; Fulvestrant, Estradiol 6mg; Gemcitabine, Navelbine; Docetaxol; Ixabepilone; possible tamoxifen--patient denies this; Nab-Paclitaxel x1 dose; Fulvestrant; Capecitabine; Carboplatin x1 dose Treatment post sample grafting: Estradiol 6mg, Methotrexate, Cyclophosphomide; Paclitaxel, Bevacizumab; Tamoxifen; Fulvestrant; Tamoxifen and Afinitor Pathology specimen type: Unknown Pathology stage: Unknown Stage at sample grafting: Unknown Pathology: Unknown Patient tumor grade: Unknown Age at diagnosis: Unknown Family history: Unknown Overall survival (months): Unknown Patient race: Unknown Propagated in NSG @ Inotiv:No Completed efficacy study: No Estradiol response: Dependent WHIM number: 24 Notes: |
| WHIM25 | Metastasis: Skin | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: WT PIK3CA genotype2: WT p53 genotype: R273H Whole genome sequenced: Yes Exome sequenced: RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: MAPK_pT202_Y204 PAM50 subtype originating tumor: Basal PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Paclitaxel with Bevacizumab followed by AC with Bevaxizumab Treatment post sample grafting: UCN1 and Irinotecan Pathology specimen type: Unknown Pathology stage: Unknown Stage at sample grafting: Unknown Pathology: Unknown Patient tumor grade: Unknown Age at diagnosis: Unknown Family history: Unknown Overall survival (months): Unknown Patient race: African American Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 25 Notes: Same patient as WHIM 5 |
| WHIM26 | Metastasis: Node | ER+ / PR+ / HER2- | ESR1 genotype: WT PIK3CA genotype2: WT p53 genotype: WT Whole genome sequenced: Yes Exome sequenced: RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: mTOR_pS2448 PAM50 subtype originating tumor: Luminal B PAM50 subtype early passage PDX: Luminal A PAM50 subtype late passage PDX: Luminal B Treatment prior to sample grafting: Premarin; Anastrozole; Estradiol; Arimidex; Estradiol, Tamoxifen Treatment post sample grafting: Xeloda, Radiation to chest wall and right supraclavicular fossa Pathology specimen type: Surgical – lymph node, right supraclavicular, biopsy Pathology stage: 2A Stage at sample grafting: 4 Pathology: Metastatic micropapillary carcinoma Patient tumor grade: Unknown Age at diagnosis: 59 Family history: None Overall survival (months): 283 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 26 Notes: |
| WHIM27 | Metastasis: Liver | ER+ / PR+ / HER2- | ESR1 genotype: Y537N PIK3CA genotype2: WT p53 genotype: Del 1022_1033 Whole genome sequenced: No Exome sequenced: Yes RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Luminal B PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Luminal B Treatment prior to sample grafting: R modified radical mastectomy; CMFx 2 (did not tolerate); FACx4 XRT chest wall; Tamoxifenx 6 months (discontinuation unknown); Recurrence in mediastinal LN and bone; Letrozole, Zometa; bone progression, R shoulder sub-q met, R scalp met; Estradiol 6 mg for 4 weeks until porogressionm; Falsodex (d/c due to progression); Xeloda (d/c due to progression); brian met; XRT 15 treatments to brian, Tamoxifen; Avastin, Taxotere; Avastin; Herceptin (no response); CMF; Avastin, Taxol; Methotrexate, Cyclephopsphamide (one dose); Carboplatin and Gemcitabine; Ixabepilone; liver met Treatment post sample grafting: Falsodex; Pathology specimen type: Liver Needle Biopsy Pathology stage: T2N1M0 (at diagnosis) Stage at sample grafting: 4 Pathology: Ductal, infiltrating Patient tumor grade: Unknown Age at diagnosis: Unknown Family history: Unknown Overall survival (months): 186 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 27 Notes: |
| WHIM29 | Primary: Breast | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: N/A Treatment post sample grafting: N/A Pathology specimen type: L breast biopsy during port placement Pathology stage: T4N3M1 (at diagnosis) Stage at sample grafting: 4 Pathology: Ductal, infiltrating Patient tumor grade: Not given Age at diagnosis: Unknown (post-menopausal) Family history: Unknown Overall survival (months): Unknown (<10 months) Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 29 Notes: |
| WHIM30 | Primary: Breast | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: N/A Treatment post sample grafting: Neo. Adj. Paclitaxel (x4 cycles) followed by Adriamycin/Cytoxon (x4 cycles) on trial; left and right breast mastectomy and left axillary node dissection (neg. for residual disease); radiation to L chest wall and regional lymphatics; bilateral ooporectomy; L breast implant removal Pathology specimen type: L Breast core biopsy Pathology stage: T3N2M0 Stage at sample grafting: T3N2M0 Pathology: Ductal, invasive Patient tumor grade: 3 Age at diagnosis: 35 (pre-menapausal) Family history: Unknown Overall survival (months): Still alive at reporting No evidence of recurrance (46) Patient race: Asian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 30 Notes: Patient BRCA2 mutation+ |
| WHIM31 | Metastasis: Adomen (sub-q) |
ER- / PR- / HER2-
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: s/p lumpectomy and radiation, adjuvant ACx4, Docetaxel x4; Recurrent L breast cancer; mastectomy; Adj. Taxol, Carboplatin; Hysterectomy and oophorectomy; Arimidex; Reccurence L breast; Tamoxifen; new nodule; Falsodex; chest soft tissue mass and lung mets; Xeloda/Avastin; Avastin stopped; Xeloda dose reduction; chest wall mass progression; Navelbine/Gemcitabine; brain mets, lung met; CMF; brain radiation; Cytotoxan; chest mass progression; Gemcitabine, Carboplatin; Eribulin; Enlargin RUL mass; Chest radiation ; Sub-q nodules in R lower quadrant of abdomen Treatment post sample grafting: Doxorubicin Pathology specimen type: Biopsy Pathology stage: 3A (at diagnosis) Stage at sample grafting: 4 Pathology: Not given Patient tumor grade: 3 (at diagnosis) Age at diagnosis: Unknown (post-menopausal) Family history: Unknown Overall survival (months): 115 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 31 Notes: Patient BRCA-1 mutation + |
| WHIM32 | Recurrance: L breast (R breast primary) |
ER+ / PR- / HER2- | ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: R modified mastectomy with LND and prophylactic L simple mastectomy; Adj. ACx4 cycles; Taxoterex4 cycles; liver mets; adj. radiation; Adj. Tamoxifen; bone mets; Falsodex, Zometa; (Abraxane, Avastin, Zometa) x 6 cycles; Avastin, Falsodex, Zometa; liver mets, reactivation of bone mets; (Avastin, Abraxane, Zometa)X 3 cyles (therpay held 8 dyas duing episode of collitis); Xeloda; Avastin, Zometa; Xelodda; Adenxal mass; Lupron, Femara; Carboplatin, Gemcitabine Treatment post sample grafting: Several treatmetn breaks, during treatmetn break had trial of Aromasin followed by single agent Carboplatin; Erubulin; Everlimus, Tamoxifen; Affinitor, Tamoxifen Pathology specimen type: L Breast Skin Biobsy Pathology stage: T2N2M0 (at diagnosis) Stage at sample grafting: 4 Pathology: Ductal, invasive Patient tumor grade: 2/3 Age at diagnosis: Unknown (post-menapausal) Family history: Unknown Overall survival (months): 35 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 32 Notes: Patient BRCA 1&2 testing negative |
| WHIM33 | Breast: Primary | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Mets to brain, lung, and liver; Whole brain radiation Treatment post sample grafting: Paclitaxel; Pathology specimen type: Repeat L breast core biopsy Pathology stage: Not given Stage at sample grafting: 4 Pathology: Ductal, invasive Patient tumor grade: 3 Age at diagnosis: Unknown (post-menopausal) Family history: Unknown Overall survival (months): 8 Patient race: African American Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 33 Notes: |
| WHIM34 | Metastasis: R thigh | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Lumpecomy; S/p whole breast radiation; mets to skin, L breast, mediastinum, liver, sacrum Treatment post sample grafting: Brain met; whole brain radiation; Abraxane; unknown Pathology specimen type: R tihgh biopsy Pathology stage: TxN0M0 (suspected T2) Stage at sample grafting: 4 Pathology: Intracystic papillary Infiltrating Patient tumor grade: Not given Age at diagnosis: Unknown (pre-menopusal) Family history: Unknown Overall survival (months): Still Alive at Reporting (52) Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 34 Notes: |
| WHIM35 in stock |
Primary: Breast | ER+ / PR+ / HER2+ | ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: Unknown Exome sequenced: Unknown RNAseq: Unknown Gene expression (microarray data) available: Unknown Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: N/A Treatment post sample grafting: Neo adj. weekly taxol plus herceptin x12 (tumor shrinkage); FEC, Herceptin Q 3 week x 4 cycles (SD); Bilateral modified radical mastectomy; Adj. Herceptin, tamoxifen (tam. Stopped for chemo), XTR of chest wall and draining lymph nodes; local chest wall reccurence and lymph (while on Herceptin); XRT and hyperthermia to left chest wall and draining lymphatics: Taxotere, Carbo and Herceptin Q3 week x 4; Herceptin; new arm mass; XRT - 15 treatments to left mid arm and new arm lesion; skin lesions; Kadcyla Q3 week; Herceptin, Perjeta, Paclitaxel Pathology specimen type: Left breast core biopsy Pathology stage: T3N3 Stage at sample grafting: T3N3 Pathology: Infiltrating Ductal Carcinoma Patient tumor grade: 2 Age at diagnosis: 45 (Pre-menopausal) Family history: Unknown Overall survival (months): 42 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 35 Notes: Bilateral primary tumors, tumor in right breast was Her2-, left Her2+ |
| WHIM36 | Metastasis: Skin | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: Unknown Exome sequenced: Unknown RNAseq: Unknown Gene expression (microarray data) available: Unknown Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Neoadj. AC x4, followed by lumpectomy/R axillary LN; Adj. taxol x12, followed by radiation; Skin met, right breast; modified radical mastectomy; Local regional inflammatory disease recurrence; Iniparib (x16), Carboplatin (x7), Gemcitabine on trial, terminated due to toxicity; Chest wall recurrence Treatment post sample grafting: Xeloda, addition of Cyclophosphamide, Local radiation Pathology specimen type: Chest wall punch biopsy Pathology stage: pT1cpN3a Stage at sample grafting: 4 Pathology: Ductal, Invasive Patient tumor grade: 3 Age at diagnosis: Unknown (pre-menopausal) Family history: Unknown Overall survival (months): 42 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 36 Notes: |
| WHIM37 | Metastasi: Left femoral head | ER+ / PR+ / HER2- | ESR1 genotype: D538G PIK3CA genotype2: WT p53 genotype: I195T, R213R Whole genome sequenced: No Exome sequenced: Yes RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Luminal B PAM50 subtype late passage PDX: Luminal B Treatment prior to sample grafting: Neo adj. AC, Taxotere; R modified radical mastectomy; Adj. Arimidex; Bone Metastasis; Radiation; Fulvestrant, Zometa; Lung metastasis; Xeloda, Zometa; Abraxane, Zometa; Left auxillary lymphnode metatasis Treatment post sample grafting: Estradiol, Zometa; Discontinuation of Estradiol, addiotn of Erbulin; Liver metastasis; Erbulin discontinued, Tamoxifen initiated; Fulvestrant, Zometa Pathology specimen type: L femoral head excision Pathology stage: Unknown Stage at sample grafting: 4 Pathology: Ductal Patient tumor grade: Not given Age at diagnosis: 58 Family history: Unknown Overall survival (months): 75 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 37 Notes: |
| WHIM39 | Metastasis: Skin | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: No Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: R mastectomy and sentinel LN biopsy w/ immediate reconstruction; Adj. Taxotere, cyclophosphamide; Adj. Arimidex; Mets to skin, LN, bone/spine Treatment post sample grafting: Radiation to thoracic spine x10 cycles; Falsodex; Doxil Pathology specimen type: Skin punch Biopsy Pathology stage: T2N0M0 (at diagnosis) Stage at sample grafting: 4 Pathology: Ductal, Invasive Patient tumor grade: 3 Age at diagnosis: Unknown (post-menopausal) Family history: Unknown Overall survival (months): 25 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 39 Notes: Path report did not discover evidency of malignancy in skin punch biopsy |
| WHIM40 | Metastasis: Left auxillary lymph node |
ER+ / PR+ / HER2- | ESR1 genotype: WT PIK3CA genotype2: WT p53 genotype: L265Q, D281G, L323L Whole genome sequenced: No Exome sequenced: Yes RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Luminal B PAM50 subtype early passage PDX: Luminal B PAM50 subtype late passage PDX: Luminal B Treatment prior to sample grafting: Unknown Treatment post sample grafting: Unknown Pathology specimen type: Unknown Pathology stage: Unknown Stage at sample grafting: 4 Pathology: Ductal Patient tumor grade: Not given Age at diagnosis: Unknown Family history: Unknown Overall survival (months): Still Alive at Reporting Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 40 Notes: |
| WHIM41 | Metastasis: Skin Chest wall | ER- (?) / PR- (?) / HER2- (?)
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Adj. AC followed by Taxol; Chest wall radiation; Chest wall and L auxillary LN reccurence; Abraxane, Avastin x3 then progressed; Chest wall reccurence; Gemzar, Xeloda x6 then progressed; Carboplatin, Taxotere; right chest wall reccurence Treatment post sample grafting: Erlubin (?), F/U Pathology specimen type: R chest wall punch biopsy Pathology stage: Unknown Stage at sample grafting: 4 Pathology: Ductal (primary) Patient tumor grade: Not given Age at diagnosis: Unknown (premenopausal) Family history: Unknown Overall survival (months): 41 Patient race: African American Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 41 Notes: ER/PR/HER2 status not reported for sample grafted. Previously TNBC. Patient sample Sequenced, neg for EGFR, MLL, ALK rearrangements |
| WHIM43 in stock |
Metastasis: Right Rib | ER+ / PR+ / HER2+ | ESR1 genotype: D538G PIK3CA genotype2: WT p53 genotype: WT Whole genome sequenced: No Exome sequenced: Yes RNAseq: Yes Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Luminal B PAM50 subtype early passage PDX: Luminal B PAM50 subtype late passage PDX: Luminal B Treatment prior to sample grafting: Adj. Doxorubicin and Cyclophosphamide x4 followed by Paclitaxel x4 followed by radiation; Tamoxifen for ~3 years; first reoccurrence; Letrozole; Arimidex; Aromasin; Taxol and Avastin; Faslodex/Zometa; progression of pulmonary pleural disease, liver lesions, and new spinal metastases; Carboplatin/Gemcitabine with Zometa followed by Eribulin Treatment post sample grafting: N/A Pathology specimen type: Right rib needle biopsy Pathology stage: Unknown Stage at sample grafting: 4 Pathology: Ductal Patient tumor grade: 3 Age at diagnosis: Unknown Family history: Unknown Overall survival (months): 81 Patient race: Caucasian Propagated in NSG @ Inotiv: x Completed efficacy study: x Estradiol response: Inhibited WHIM number: 43 Notes: |
| WHIM51 | Recurrence/Metastasis: Chest wall |
ER+ / PR+ / HER2+ | ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: L mastectomy; Adj. CMF; Radiation; Tamoxifen; Tamoxifen discontinued due to headaches; Thyroid gland metastasis; Tamoxifen and Zoladex; Tamoxifgen d/c due to progression; Bone met; Zoladex, herceptin, letrozole; discontinued due to bone met progression; Exemestane and Lupron; Herceptin added; Exemestane d/c due to plural effusion; Herceptin, Lupron; Fulvestrant started; Discontinued due to progression; lung met; Xeloda, discontinued due to progression; Exemestane, goserelin, addition of metronomic chemotherpay w/ cyclophosphamide, methotrexate; Treatment post sample grafting: Gemcitabine, carboplatin; d/c due to progression in omentum and peritoneum; Paclitaxel d/c due to progression; Armoasin, Everlimus, d/c due to acute renal failure; Anostrozole; brain met; whole brain radiation; Anastrozole d/c; Lapatinib Pathology specimen type: Skin punch Biopsy Pathology stage: pT2N0 (at diagnosis) Stage at sample grafting: 4 Pathology: Not given Patient tumor grade: Not given Age at diagnosis: 36 Family history: Unknown Overall survival (months): 51 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 51 Notes: Patient BRCA negative |
| WHIM53 | Metastasis/Reccurence: Left Breast Skin | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Refused adj. chemo and radiation; skin thickening w/ mulitple hypermetabolic foci in lung and breast and LN mets; Taxotere Treatment post sample grafting: Brain met; whole brain radiation Pathology specimen type: Left breast skin punch biopsy Pathology stage: Unknown Stage at sample grafting: Unknown Pathology: Invasive ductal Patient tumor grade: 3 Age at diagnosis: Unknown (post-menopausal) Family history: Unknown Overall survival (months): 19 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 53 Notes: |
| WHIM55 | Recurrence/Metastasis: Chest wall |
ER- / PR- / HER2-
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting:Lumpectomy and sentinel LN dissection; axillary LN dissection; Adj. Adriamycin, Cytoxan followed by Taxol; R chest wall and LN radition; Bone met and chest wall recurrence; Capecitabine, discontinued due to increased nodularity; radiation Treatment post sample grafting: Paclitaxel, discontinued due to disease progression; unknown Pathology specimen type: Skin punch Biopsy Pathology stage: Unknown Stage at sample grafting: 4 Pathology: Not given Patient tumor grade: Not given Age at diagnosis: 45 Family history: Unknown Overall survival (months): 34 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 55 Notes: Patient BRCA1,2 negative |
| WHIM56 | Primary: Breast | ER- / PR- / HER2+ | ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: N/A Treatment post sample grafting: THP; therapies stopped due to heart failure; unknown Pathology specimen type: R core biopsy during port placement Pathology stage: Not given Stage at sample grafting: 4 Pathology: Ductal, invasive Patient tumor grade: 3 Age at diagnosis: 29 (pre-menopausal) Family history: Unknown Overall survival (months): Still alive at reporting (32) Patient race: African American Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 56 Notes: |
| WHIM58 | Metastasis: Sternum | ER+ / PR+ / HER2- | ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Neo adj. Anastrazole,; FEC-T; R modified mastectomy; adj. Anastrozole; bone, liver, lymph mets Treatment post sample grafting: Palliative Gemcitabine and Carboplatin; Palliative Erublin; brain met; whole brain radiation Pathology specimen type: Bx of sternal lesion Pathology stage: Not given Stage at sample grafting: 4 Pathology: Ductal, invasive Patient tumor grade: 1 Age at diagnosis: 54 (post-menopausal) Family history: Unknown Overall survival (months): 36 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 58 Notes: |
| WHIM59 | Metastasis/Recurrence: Unknown |
ER+ (initial) - / PR+ (initial) - / HER2+ (initial) - | ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Partial mastectomy and sentinal LN bx; Adj. Taxotere and Cyclophosphamidex4; Arimidex; R breast radiation; skin punch bx TNBC, met to LN, lung, GI and bones Treatment post sample grafting: Adriamycin, Cytoxanx2, discontinued due to side effects; Xgeva, Pacliataxel; Eribulin; Doxorubicin (liposomal), B chest wall radiation; New bone mets, increased aux. LN mets; CMF; end tx Pathology specimen type: Unknown Pathology stage: T1cN0 (at diagnosis) Stage at sample grafting: 4 Pathology: Ductal, invasive Patient tumor grade: 3 Age at diagnosis: 58 Family history: Unknown Overall survival (months): 99 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 59 Notes: |
| WHIM62 | Metastasis: Inguinal LN | ER+ / PR+ / HER2- | ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: No Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: R. modified radical mastectomy; Adjuvant ACx4; R chest wall and node radiation; Arimidex; bone met; CyberKnife surgery and Aromasin; widespred bone and LN mets; palliative radiation to hip and ribs; Xgeva Treatment post sample grafting: Fulvestrant, Xegeva; addition of Affinitor; Aromasin added Pathology specimen type: LN Biobsy Pathology stage: pT1cN1M0 (at diagnosis) Stage at sample grafting: 4 Pathology: Ductal, invasive Patient tumor grade: 3 Age at diagnosis: Unknown (post-menopausal) Family history: Unknown Overall survival (months): Still alive at reporting (106) Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 62 Notes: Patient BRACA2+ |
| WHIM63 in stock |
Primary: Left Breast | ER+ / PR- / HER2- | ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: N/A (treatment naïve) Treatment post sample grafting: Neo adj. AC (x4, skin rash); Epirubicin, Cytoxan; DD taxol; Mastectomy; Goserelin and Exemestane (discontinued due to PD); Metastasis to liver and bone; Sample grafted for WHIM 70; Xeloda, Ruxolitinib/placebo, Boniva on trial; Consent for neratinib Her2 mutation trial; tx switched to Eribulin due to PD; tx switched to Carboplatin and Gemcitabine due to PD Pathology specimen type: Left breast biopsy during port placement Pathology stage: cT2N0Mx Stage at sample grafting: cT2N0Mx Pathology: Ductal, invasive Patient tumor grade: 3 Age at diagnosis: 33 Family history: Unknown Overall survival (months): 15 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 63 Notes: Same Patient as WHIM70 |
| WHIM64 | Recurrence: L Chest wall, skin |
ER+ / PR- / HER2- | ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Neo-adj. TAC, minimal response; Arimidex; reccurence and LN met; Radiation, low dose Xeloda, hyperthermia; spinal lesions; Tamoxifen; progression in soft tissue and bone; Xeloda, mammoglobin vaccine on study; Affinitor, Aromasin, continued on mammaglobin trial; 4 new spinal lesions; Affinitor, Aromasin on study; Affinitor dose lowered due to mouth sores and weight loss; nodules in chest wall Treatment post sample grafting: Unknown Pathology specimen type: Left chest wall skin punch biopsy Pathology stage: 3B, T2N3a Stage at sample grafting: 4 Pathology: Lobular Invasive Patient tumor grade: Not given Age at diagnosis: Unknown (premenopausal) Family history: Unknown Overall survival (months): Unknown Patient race: Unknown Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 64 Notes: |
| WHIM65 | Residual Primary: Breast | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Neo adj. Carboplatin+Docetaxelx6; R lumpectomy Treatment post sample grafting: Dose-dense Adriamycin and Cyclophosphamidex4; radiation; unknown Pathology specimen type: Definitve surgery Pathology stage: Not given Stage at sample grafting: Not specified 1/3 LN+ Pathology: Ductal, invasive Patient tumor grade: 3 Age at diagnosis: 48 (pre-menopausal) Family history: Unknown Overall survival (months): Still alive at reporting (19) Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 65 Notes: Patient BRACA1,2 negative |
| WHIM66 | Metastatic/Recurrent: Chest Wall |
ER- / PR- / HER2-
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: No Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Neo adj. Tacol; Neo adj. FAC; L partial mastectomy w L aux. node dissection; Bilateral mastectomy; adj. radiation; chest wall and L internal mamary node reccurence; excisional biopsies; Carboplatin Treatment post sample grafting: Recurrence in L chest wall and R axcilla; CDX-11 on trial; lung nodule (CDX-11 continued); Eribulin; unknown Pathology specimen type: Skin punch Biopsy Pathology stage: cT2N1mx (at diagnosis) Stage at sample grafting: 4 Pathology: Ductal, invasive Patient tumor grade: 3 Age at diagnosis: 48 (pre-menopausal) Family history: Unknown Overall survival (months): Still alive at reporting (26) Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 66 Notes: |
| WHIM68 | Primary: Breast | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: N/A Treatment post sample grafting: Neo. Adj. Docetaxel, Carboplatinx6; C1D3 bx; L simple mastectomy w/ axillary LN dissection w/ axillary sentinel LN bx and R prophylctic mastectomy and B breast reconstruction; 1/3 pos sentinel LN; radiation to L chest wall and regional LNs; lung mets; liver mets; Eribulin+Pembrolzumab on trial; R leg DVT; BID Lovenox Pathology specimen type: Breast biopsy during port placement Pathology stage: Unknown Stage at sample grafting: 4 Pathology: Ductal, invasive Patient tumor grade: 3 Age at diagnosis: 56 (pre-menopausal) Family history: Unknown Overall survival (months): Unknown Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 68 Notes: Patient BRCA1/2 negative Same patient as WHIMs 69, 74, 75 |
| WHIM69 | Primary: Breast (C1D3) | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Neo. Adj. Docetaxel, Carboplatinx6; C1D3 bx Treatment post sample grafting: L simple mastectomy w/ axillary LN dissection w/ axillary sentinel LN bx and R prophylctic mastectomy and B breast reconstruction; 1/3 pos sentinel LN; radiation to L chest wall and regional LNs; lung mets; liver mets; Eribulin+Pembrolzumab on trial; R leg DVT; BID Lovenox Pathology specimen type: C1D3 core breast biopsy Pathology stage: Unknown Stage at sample grafting: 4 Pathology: Ductal, invasive Patient tumor grade: 3 Age at diagnosis: 56 (pre-menopausal) Family history: Unknown Overall survival (months): Unknown Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 69 Notes: Patient BRCA1/2 negative Same patient as WHIMs 68, 74, 75 |
| WHIM70 | Metastasis: Liver | ER+ / PR- / HER2- | ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Sample grafted for WHIM 63; Neo adj. AC (x4, skin rash); Epirubicin, Cytoxan; DD taxol; Mastectomy; Goserelin and Exemestane (discontinued due to PD); Metastasis to liver and bone; Treatment post sample grafting: Xeloda, Ruxolitinib/placebo, Boniva on trial; Consent for neratinib Her2 mutation trial; tx switched to Eribulin due to PD; tx switched to Carboplatin and Gemcitabine due to PD Pathology specimen type: Liver Biopsy Pathology stage: cT2N0Mx Stage at sample grafting: 4 Pathology: Ductal, invasive Patient tumor grade: 3 Age at diagnosis: 33 Family history: Unknown Overall survival (months): 15 Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 70 Notes: Same Patient as WHIM63 |
| WHIM71 | Primary: Breast | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: No Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: N/A Treatment post sample grafting: Neoadj. Docetaxel, Carboplatin; R lumpectomy w/ sentinel LN biopsy; Adj. radiation to R whole breast x2 Pathology specimen type: Tissue collection during port placement Pathology stage: Not given Stage at sample grafting: 2 Pathology: Ductal, invasive Patient tumor grade: 3 Age at diagnosis: 57 (pre-menopausal) Family history: Unknown Overall survival (months): Still alive at reporting (20) Patient race: African American Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 71 Notes: |
| WHIM72 in stock |
Primary: Right Breast | ER+ / PR- / HER2- | ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: N/A (treatment naïve) Treatment post sample grafting: Neo adj. chemo FEC x4; Bilateral Mastectomy w/ auxiliary LN dissection, 10/38 nodes; Taxol switched to Taxotere for cycle 2 due to joint pain; Chest wall radiation; Hormonal Therapy w/ Exemestane plus Triptorelin; Bilateral oophorectomy; Bone met L5; Radiation therapy to L2-L5 plus R hip; Fulvestrant, Palbociclib (42 days stopped due to PD); Erubilin (25% dose reduction to toxicities, stopped due to PD); Enrollment on BIBF-1120 multi-targeted kinase inhibitor trial; Liver met Pathology specimen type: R core biopsy during port placement Pathology stage: Unknown Stage at sample grafting: Unknown Pathology: Ductal, invasive Patient tumor grade: 3 Age at diagnosis: 31 Family history: Unknown Overall survival (months): 26 Patient race: Unknown Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 72 Notes: |
| WHIM73 | Recurrence/Met: Chest wall | ER+ / PR- / HER2- | ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Yes Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Right mastectomy and LN dissection; ACx4, Tx3; Tamoxifen; Aromasin; recurrence with metastasis soft-tissue mass in anterior R chest wall, adenopathy Treatment post sample grafting: Weekly taxol; Carboplatin AUC of 2, changed to 1.5 every 2 weeks; taxol discontinued due to neuropathy; Carboplatin discontinued Letrozole and Palbociclib ongoing at reporting Pathology specimen type: Chest wall biopsy Pathology stage: T2N1M0 (at diagnosis) Stage at sample grafting: 4 Pathology: Not given Patient tumor grade: Not given Age at diagnosis: Unknown (post-menopausal) Family history: Unknown Overall survival (months): Still alive at reporting (>192 ) Patient race: African American Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 73 Notes: |
| WHIM74 | Unknown | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: No Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Neo. Adj. Docetaxel, Carboplatinx6; C1D3 bx Treatment post sample grafting: L simple mastectomy w/ axillary LN dissection w/ axillary sentinel LN bx and R prophylctic mastectomy and B breast reconstruction; 1/3 pos sentinel LN; radiation to L chest wall and regional LNs; lung mets; liver mets; Eribulin+Pembrolzumab on trial; R leg DVT; BID Lovenox Pathology specimen type: Unclear, LN dissection or mastectomy Pathology stage: Unknown Stage at sample grafting: 4 Pathology: Ductal, invasive Patient tumor grade: 3 Age at diagnosis: 56 (pre-menopausal) Family history: Unknown Overall survival (months): Unknown Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 74 Notes: Patient BRCA1/2 negative Same patient as WHIMs 68, 69, 75 |
| WHIM75 | Metastasis: Liver | ER- / PR- / HER2-
TNBC
|
ESR1 genotype: Unknown PIK3CA genotype2: Unknown p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: No Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: L simple mastectomy w/ axillary LN dissection w/ axillary sentinel LN bx and R prophylctic mastectomy and B breast reconstruction; 1/3 pos sentinel LN; radiation to L chest wall and regional LNs; lung mets; liver mets; Treatment post sample grafting: Eribulin+Pembrolzumab on trial; R leg DVT; BID Lovenox Pathology specimen type: Liver biopsy Pathology stage: Unknown Stage at sample grafting: 4 Pathology: Ductal, invasive Patient tumor grade: 3 Age at diagnosis: 56 (pre-menopausal) Family history: Unknown Overall survival (months): Unknown Patient race: Caucasian Propagated in NSG @ Inotiv: No Completed efficacy study: No Estradiol response: Unknown WHIM number: 75 Notes: Patient BRCA1/2 negative Same patient as WHIMs 68, 69, 74 |
| WHIM81 Available at Washington University in St. Louis |
Metastasis: Liver | ER+ / PR- / HER2- | ESR1 genotype: Unknown PIK3CA genotype2: Under investigation p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: No Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Unknown Treatment prior to sample grafting: Neo-adj. Arimidex; Adj. Chemo FEC-Tx3 cycles; Arimidex; recurance in bone; Radiation; BKM120/placebo eith Fulvestrant on study; Xeloda interrupted by radiation to left proximal femur; Palbociclib; Regorafenib, Rafemetinib; Erlubin; Carboplatin, Gemcitabine (\ Carboplatin switched to cisplatin); Palbociclib, Letrozole; Liver met Treatment post sample grafting: Brain met; Whole brain radiation Pathology specimen type: Liver Biopsy Pathology stage: T3N1M0 Stage at sample grafting: 4 Pathology: Ductal Patient tumor grade: Not given Age at diagnosis: Unknown (post-menopausal) Family history: Unknown Overall survival (months): 110 Patient race: Caucasian Propagated in NSG @ Inotiv: Yes Completed efficacy study: Yes Estradiol response: Unknown WHIM number: 81 Notes: Patient biopsy was PR+ but PDX tumor is PR- |
| WHIM84 in stock |
Metastasis: Bone L1 | ER+ / PR+ / HER2- | ESR1 genotype: Unknown PIK3CA genotype2: Under investigation p53 genotype: Unknown Whole genome sequenced: No Exome sequenced: No RNAseq: No Gene expression (microarray data) available: Unknown Highest ranked phosphoprotein: Unknown PAM50 subtype originating tumor: Unknown PAM50 subtype early passage PDX: Unknown PAM50 subtype late passage PDX: Neo. Adj. MK-2206 on trial, continued on Arimidex alone; sentinel; node positive for metastasis; Adj. TCx4; Radiation; Anastrozole; Bone met (L1) Treatment prior to sample grafting: Radiation to spine and left femur; CMF, discontinued due to progression; Fulvestrant with addition of Palbociclib; Brain met; Cepecitabine; Unknown Treatment post sample grafting: Bone L1 Biopsy Pathology specimen type: cT2N0 Pathology stage: 4 Stage at sample grafting: Ductal; Invasive Pathology: Not given Patient tumor grade: Unknown (post-menopausal) Age at diagnosis: Unknown Family history: Alive at reporting (57 months) Overall survival (months): Caucasian Patient race: In Progress Propagated in NSG @ Inotiv: Yes Completed efficacy study: In progress Estradiol response: Unknown WHIM number: 84 Notes: Patient biopsy was PR- but PDX tumor is PR+ |
Subscribe to updates from Inotiv
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
